Core Viewpoint - BeiGene (688235.SH) has adjusted its revenue forecast for the fiscal year 2025, projecting revenue between RMB 36.2 billion and RMB 38.1 billion, driven by the strong market position of its product, BeiYueZe®, in the U.S. and its ongoing expansion in Europe and other key global markets [1] Revenue Adjustment - The adjusted revenue forecast for 2025 is set between RMB 36.2 billion and RMB 38.1 billion [1] - The increase in revenue is primarily attributed to the leading position of BeiYueZe® in the U.S. market and its continuous expansion in Europe and other significant global markets [1] Expense Adjustment - Research and development expenses, along with sales and management expenses, are projected to be between RMB 29.5 billion and RMB 30.9 billion [1] - The adjustments in expenses are mainly due to prudent investment strategies that promote revenue growth and pipeline expansion, resulting in significant operational efficiency [1]

Core Viewpoint - The company, BeiGene, has voluntarily disclosed an adjustment to its 2025 operating performance forecast, indicating a positive outlook driven by market expansion and improved product mix [1]. Group 1: Adjusted Performance Forecast - The adjusted revenue forecast for 2025 is now between RMB 35.8 billion and RMB 38.1 billion, up from the previous estimate of RMB 35.2 billion to RMB 38.1 billion [1]. - Research and development expenses, along with sales and management costs, remain unchanged, projected between RMB 29.5 billion and RMB 31.9 billion [1]. - The gross profit margin is expected to be in the higher range of 80% to 90%, reflecting improvements in product mix and production efficiency [1]. Group 2: Reasons for Adjustment - The increase in revenue expectations is attributed to BeiGene's leading position in the U.S. market and ongoing expansion in Europe and other key global markets [1]. - The anticipated improvement in gross margin is primarily due to enhancements in product mix and production efficiency [1].